Inclusion Criteria:  Diagnosed Osteoporosis by DXA (BMD t-score ≤ -2.5 with or without fragility fractures); Age ≥ 40 years; Females; White race; Normal levels of Vitamin D, and Absence of all exclusion criteria on clinical workup.  Patients diagnosed as osteoporotic due to the presence of fragility fractures, but without osteoporotic t-scores, will not be included because they would require fractures as a study endpoint which would entail a multi-center approach. Moreover, abnormal bone quality has been shown to be present in these patients, which requires bone histology for assessment.  Exclusion Criteria:  Malignancy within the prior 5 years metastatic to bone or requiring chemotherapy (except non-melanoma skin cancers or cervical carcinoma in situ); Metabolic bone diseases (including osteomalacia, primary hyperparathyroidism and other hypercalcemic disorders, Osteogenesis Imperfecta, Paget's disease, etc.); Endocrinopathy (e.g., current hyperthyroidism, untreated hypothyroidism, Cushing's syndrome; Other medical diseases (e.g., eating disorders, end stage liver, heart or lung disease, intestinal malabsorption, chronic kidney disease stages 2-5D); Any use of antiresorbers (e.g., alendronate, actonel, denosumab) or use within the last two years of anabolic agents (e.g., teriparatide, abaloparatide); Use within the prior year of glucocorticoids, hormone replacement therapy, calcitonin, selective estrogen receptor modulators or phenytoin; Pregnancy, desire to get pregnant, or nursing; Allergy to tetracycline; prior external beam or implant radiation therapy; use of non-aspirin anticoagulants that cannot be safely stopped for the biopsy; prisoners; and radius BMD t-score ≤ -3.5.